Japanese Society of Allergology. Japanese guidelines for adult asthma 2020
-
- Nakamura Yoichi
- Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital
-
- Tamaoki Jun
- First Department of Medicine, Tokyo Women's Medical University
-
- Nagase Hiroyuki
- Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine
-
- Yamaguchi Masao
- Third Department of Medicine, Teikyo University Chiba Medical Center
-
- Horiguchi Takahiko
- Department of Respiratory Medicine, Fujita Health University Bantane Hospital
-
- Hozawa Soichiro
- Hiroshima Allergy and Respiratory Clinic
-
- Ichinose Masakazu
- Department of Respiratory Medicine, Tohoku University Graduate School of Medicine
-
- Iwanaga Takashi
- Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
-
- Kondo Rieko
- Department of Respiratory Medicine, Fujita Health University Bantane Hospital
-
- Nagata Makoto
- Department of Respiratory Medicine, Saitama Medical University Hospital
-
- Yokoyama Akihito
- Department of Hematology and Respiratory Medicine, Kochi University
-
- Tohda Yuji
- Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
書誌事項
- タイトル別名
-
- Japanese guidelines for adult asthma 2020
この論文をさがす
説明
<p>Bronchial asthma is characterized by chronic airway inflammation, which manifests clinically as variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma may induce airway remodeling and become intractable. The prevalence of asthma has increased; however, the number of patients who die from it has decreased (1.3 per 100,000 patients in 2018). The goal of asthma treatment is to control symptoms and prevent future risks. A good partnership between physicians and patients is indispensable for effective treatment. Long-term management with therapeutic agents and the elimination of the triggers and risk factors of asthma are fundamental to its treatment. Asthma is managed by four steps of pharmacotherapy, ranging from mild to intensive treatments, depending on the severity of disease; each step includes an appropriate daily dose of an inhaled corticosteroid, which may vary from low to high. Long-acting β2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs, while anti-immunoglobulin E antibodies and other biologics, and oral steroids are reserved for very severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by selecting treatment steps for asthma based on the severity of the exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-exacerbated respiratory disease, and pregnancy are also important conditions to be considered in asthma therapy.</p>
収録刊行物
-
- Allergology International
-
Allergology International 69 (4), 519-548, 2020
一般社団法人日本アレルギー学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1391975276375122048
-
- NII論文ID
- 130007926252
-
- ISSN
- 14401592
- 13238930
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可